As of 2025-11-18, the EV/EBITDA ratio of Basilea Pharmaceutica AG (BSLN.SW) is 7.53. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BSLN.SW's latest enterprise value is 576.33 mil CHF. BSLN.SW's TTM EBITDA according to its financial statements is 76.56 mil CHF. Dividing these 2 quantities gives us the above BSLN.SW EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 3.4x - 7.5x | 5.4x |
| Forward P/E multiples | 8.2x - 11.0x | 9.6x |
| Fair Price | 23.02 - 61.85 | 44.61 |
| Upside | -50.8% - 32.3% | -4.6% |
| Date | EV/EBITDA |
| 2025-11-14 | 7.55 |
| 2025-11-13 | 7.63 |
| 2025-11-12 | 7.55 |
| 2025-11-11 | 7.42 |
| 2025-11-10 | 7.28 |
| 2025-11-07 | 7.21 |
| 2025-11-06 | 7.23 |
| 2025-11-05 | 7.32 |
| 2025-11-04 | 7.51 |
| 2025-11-03 | 7.28 |
| 2025-10-31 | 7.48 |
| 2025-10-30 | 7.44 |
| 2025-10-29 | 7.42 |
| 2025-10-28 | 7.53 |
| 2025-10-27 | 7.55 |
| 2025-10-24 | 7.74 |
| 2025-10-23 | 7.88 |
| 2025-10-22 | 7.84 |
| 2025-10-21 | 7.86 |
| 2025-10-20 | 7.85 |
| 2025-10-17 | 7.77 |
| 2025-10-16 | 7.90 |
| 2025-10-15 | 7.78 |
| 2025-10-14 | 7.85 |
| 2025-10-13 | 7.88 |
| 2025-10-10 | 7.94 |
| 2025-10-09 | 8.09 |
| 2025-10-08 | 8.18 |
| 2025-10-07 | 8.23 |
| 2025-10-06 | 7.88 |
| 2025-10-03 | 7.87 |
| 2025-10-02 | 7.78 |
| 2025-10-01 | 7.70 |
| 2025-09-30 | 7.62 |
| 2025-09-29 | 7.42 |
| 2025-09-26 | 7.26 |
| 2025-09-25 | 7.41 |
| 2025-09-24 | 7.44 |
| 2025-09-23 | 7.52 |
| 2025-09-22 | 7.56 |
| 2025-09-19 | 7.70 |
| 2025-09-18 | 7.34 |
| 2025-09-17 | 7.41 |
| 2025-09-16 | 7.38 |
| 2025-09-15 | 7.30 |
| 2025-09-12 | 7.48 |
| 2025-09-11 | 7.39 |
| 2025-09-10 | 7.42 |
| 2025-09-09 | 7.45 |
| 2025-09-08 | 7.48 |